ClassID:

110539

C12N2750/14132 - CPC Classification

Classification description:

ssDNA viruses; Details; Parvoviridae; Dependovirus, e.g. adenoassociated viruses Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Recent Application in this class:
#1
20260139234
2026-05-21

METHOD FOR THE PRODUCTION OF RECOMBINANT AAV PARTICLE PREPARATIONS

#2
20260117234
2026-04-30

GENE SEQUENCE CONSTRUCT USED FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES

#3
20260109979
2026-04-23

NUCLEIC ACID REGULATORY ELEMENTS FOR GENE EXPRESSION IN THE LIVER AND METHODS OF USE

#4
20260060221
2026-03-05

METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTION

#5
20250382588
2025-12-18

CHIMERIC AAV AND USES THEREOF

#6
20250381298
2025-12-18

DUAL AAV-MYO7A VECTORS WITH IMPROVED SAFETY FOR THE TREATMENT OF USH1B

#7
20250332224
2025-10-30

Adeno-Associated Virus Factor VIII Vectors

#8
20250325705
2025-10-23

GENE THERAPY

#9
20250312400
2025-10-09

Intrathecal Delivery of Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2

#10
20250305001
2025-10-02

Genetic Construct

#11
20250122497
2025-04-17

MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP)

#12
20250122267
2025-04-17

Gene Therapy Methods for Age-Related Diseases and Conditions

#13
20250109408
2025-04-03

METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE

#14
20250109407
2025-04-03

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE

#15
20250101468
2025-03-27

DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY

#16
20250073353
2025-03-06

FACTOR VIII (FVIII) GENE THERAPY METHODS

#17
20250066434
2025-02-27

Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof

#18
20250066433
2025-02-27

Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof

#19
20250059564
2025-02-20

VIRAL VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING CYTOKINES AND USES THEREOF FOR TREATING CANCER

#20
20250051740
2025-02-13

TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) PRODUCED BY HUMAN NEURAL OR GLIAL CELLS

#21
20250027058
2025-01-23

ADENOVIRUSES AND METHODS FOR USING ADENOVIRUSES

#22
20250011810
2025-01-09

RECOMBINANT AAV FORMULATIONS

#23
20250001015
2025-01-02

AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA

#24
20240376441
2024-11-14

HIGH ACTIVITY REGULATORY ELEMENTS

#25
20240318201
2024-09-26

RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF DUX4

#26
20240307511
2024-09-19

AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I

#27
20240287471
2024-08-29

GENE THERAPIES FOR LYSOSOMAL DISORDERS

#28
20240240180
2024-07-18

RAAV-BASED COMPOSITIONS AND METHODS

#29
20240207447
2024-06-27

Recombinant Adeno-Associated Vectors For Targeted Treatment

#30
20240167002
2024-05-23

Compositions and Methods for Producing Recombinant AAV

#31
20240166700
2024-05-23

ENGINEERED LIGHT-SENSITIVE PROTEINS

#32
20240150410
2024-05-09

AAV COMPOSITIONS HAVING HIGH EXPRESSION LEVELS IN BRAIN

#33
20240026307
2024-01-25

Adenoviruses and methods for using adenoviruses

#34
20240009327
2024-01-11

GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS IIIB

#35
20230365943
2023-11-16

Adenoviruses and methods for using adenoviruses

#36
20230346985
2023-11-02

ADENO-ASSOCIATED VIRUS VECTORS

#37
20230321164
2023-10-12

Intrathecal Delivery of Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2

#38
20230257771
2023-08-17

AAV DELIVERY SYSTEM FOR LUNG CANCER TREATMENT

#39
20230210884
2023-07-06

Immunomodulating Gene Therapy

#40
20230190965
2023-06-22

TREATMENT OF GLYCOGEN STORAGE DISEASE III

#41
20230149565
2023-05-18

DUAL AAV-MYO7A VECTORS WITH IMPROVED SAFETY FOR THE TREATMENT OF USH1B

#42
20230025574
2023-01-26

Recombinant Adeno-Associated Virus Delivery of Exon 2-Targeted U7SNRNA Polynucleotide Constructs

#43
20230025279
2023-01-26

CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10)

#44
20220339297
2022-10-27

HUMAN GENE THERAPY METHODS FOR HEMOPHILIA A

#45
20220339262
2022-10-27

Adeno-associated virus factor VIII vectors

#46
20220307055
2022-09-29

IMPROVED PRODUCTION OF RECOMBINANT AAV USING EMBRYONATED AVIAN EGGS

#47
20220288233
2022-09-15

GENE THERAPY FOR TREATING HEMOPHILIA B

#48
20220204974
2022-06-30

RAAV-based compositions and methods

#49
20220183613
2022-06-16

REAGENTS AND METHODS FOR MODULATING CONE PHOTORECEPTOR ACTIVITY

#50
20220162638
2022-05-26

Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer

#51
20220125952
2022-04-28

DELIVERY OF POLYNUCLEOTIDES USING RECOMBINANT AAV9

#52
20220125875
2022-04-28

AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE

#53
20220090128
2022-03-24

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE

#54
20220049247
2022-02-17

Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)

#55
20210395778
2021-12-23

Codon optimized otoferlin AAV dual vector gene therapy

#56
20210393713
2021-12-23

COMPOSITIONS AND METHODS USEFUL FOR TARGETING THE BLOOD-BRAIN BARRIER

#57
20210355453
2021-11-18

ADENOVIRUSES AND METHODS FOR USING ADENOVIRUSES

#58
20210340565
2021-11-04

METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE

#59
20210332383
2021-10-28

Adeno associated virus vectors for the treatment of hunter disease

#60
20210253644
2021-08-19

CAPSID-MODIFIED, RAAV3 VECTOR COMPOSITIONS AND METHODS OF USE IN GENE THERAPY OF HUMAN LIVER CANCER

#61
20210198739
2021-07-01

METHODS FOR DETERMINING THE PRESENCE OR RISK OF DEVELOPING FACIOSCAPULOHUMERAL DYSTROPHY (FSHD)

#62
20210180031
2021-06-17

RECOMBINANT AAVS HAVING USEFUL TRANSCYTOSIS PROPERTIES

#63
20210040156
2021-02-11

CAPSID-MODIFIED RAAV VECTORS AND METHODS OF USE

#64
20200405882
2020-12-31

Recombinant adeno-associated vectors for targeted treatment

#65
20200405810
2020-12-31

Efficient systemic treatment of dystrophic muscle pathologies

#66
20200392541
2020-12-17

Delivery and use of the CRISPR-CAS systems, vectors and compositions for hepatic targeting and therapy

#67
20200339988
2020-10-29

RAAV-based compositions and methods

#68
20200339960
2020-10-29

Methods and materials for NT-3 gene therapy

#69
20200339638
2020-10-29

Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof

#70
20200337279
2020-10-29

Large animal model for developing therapeutic agents to treat impaired ophthalmic function in usher syndrome

#71
20200332265
2020-10-22

Gene therapies for lysosomal disorders

#72
20200325454
2020-10-15

VECTORS CONTAINING AIMP2-DX2 AND TARGET NUCLEIC ACIDS FOR miR 142 AND USES THEREOF

#73
20200318108
2020-10-08

Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)

#74
20200308582
2020-10-01

KCNK3-BASED GENE THERAPY OF CARDIAC ARRHYTHMIA

#75
20200297872
2020-09-24

DELIVERY OF POLYNUCLEOTIDES USING RECOMBINANT AAV9

#76
20200289675
2020-09-17

Gene therapy for mucopolysaccharidosis IIIB

#77
20200289673
2020-09-17

Treatment of glycogen storage disease III

#78
20200283739
2020-09-10

Compositions and methods for producing recombinant AAV

#79
20200261598
2020-08-20

ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING MUCOLIPIDOSIS TYPE II

#80
20200248149
2020-08-06

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS RESTRICTING OFF-TARGET TRANSDUCTION IN LIVER AND USES THEREOF

#81
20200239859
2020-07-30

Life-cycle-defective adenovirus helper viruses, their production and use for producing rAAV

#82
20200237930
2020-07-30

FACTOR VIII (FVIII) GENE THERAPY METHODS

#83
20200231943
2020-07-23

High activity regulatory elements

#84
20200179467
2020-06-11

Intrathecal delivery of recombinant adeno-associated virus encoding Methyl-CpG binding protein 2

#85
20200171109
2020-06-04

Method for inducing production of vascular endothelial growth factor

#86
20200164008
2020-05-28

APHERESIS METHODS AND USES

#87
20200157569
2020-05-21

Genetic construct

#88
20200157564
2020-05-21

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE

#89
20200157510
2020-05-21

Adenoviruses and methods for using adenoviruses

#90
20200155624
2020-05-21

Compositions and methods of treating Huntington's disease

#91
20200149066
2020-05-14

Method for Introducing Polynucleotide to Male Germ Cell or Sertoli Cell

#92
20200149019
2020-05-14

Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells

#93
20200147185
2020-05-14

AAV9-mediated gene therapy for treating mucopolysaccharidosis type I

#94
20200101140
2020-04-02

Adeno-associated virus factor VIII vectors

#95
20200087358
2020-03-19

Engineered light-sensitive proteins

#96
20200054711
2020-02-20

REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF NEURAL INJURY CAUSED BY DISRUPTION OF BLOOD FLOW

#97
20200040360
2020-02-06

Genetic construct

#98
20200032220
2020-01-30

Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery

#99
20200024579
2020-01-23

Liver targeting adeno-associated viral vectors

#100
20200017849
2020-01-16

CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)

#101
20190390184
2019-12-26

Acid-alpha glucosidase variants and uses thereof

#102
20190345224
2019-11-14

Gene therapy methods for age-related diseases and conditions

#103
20190300903
2019-10-03

Recombinant virus products and methods for inhibition of expression of DUX4

#104
20190276822
2019-09-12

Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs

#105
20190275345
2019-09-12

REMOTE CONTROL OF LIGHT-TRIGGERED VIROTHERAPY

#106
20190240353
2019-08-08

AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA

#107
20190224257
2019-07-25

Drug composition for angiogenesis therapy

#108
20190211327
2019-07-11

RAAV-based compositions and methods

#109
20190175764
2019-06-13

Gene therapy

#110
20190167762
2019-06-06

Efficient systemic treatment of dystrophic muscle pathologies

#111
20190085301
2019-03-21

Recombinant AAVS having useful transcytosis properties

#112
20190076550
2019-03-14

Gene therapy for treating hemophilia B

#113
20190076458
2019-03-14

METHODS AND COMPOSITIONS FOR ATTENUATING GENE EXPRESSION MODULATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES

#114
20190030189
2019-01-31

DELIVERY OF POLYNUCLEOTIDES USING RECOMBINANT AAV9

#115
20190030059
2019-01-31

Immunomodulating gene therapy

#116
20190002915
2019-01-03

COMPOSITIONS AND METHODS FOR REGULATABLE ANTIBODY EXPRESSION

#117
20180355354
2018-12-13

Promoters and uses thereof

#118
20180344877
2018-12-06

Recombinant promoters and vectors for protein expression in liver and use thereof

#119
20180344197
2018-12-06

Reagents and methods for modulating cone photoreceptor activity

#120
20180334687
2018-11-22

METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE

#121
20180289757
2018-10-11

MUTANT ADENO-ASSOCIATED VIRUS VIRIONS AND METHODS OF USE THEREOF

#122
20180282702
2018-10-04

Chimeric adeno-associated virus/ bocavirus parvovirus vector

#123
20180265865
2018-09-20

RAAV-BASED COMPOSITIONS AND METHODS

#124
20180256752
2018-09-13

Selective gene therapy expression system

#125
20180223312
2018-08-09

Capsid-modified, RAAV3 vector compositions and uses in gene therapy of human liver cancer

#126
20180195058
2018-07-12

CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)

#127
20180163227
2018-06-14

Recombinant adeno-associated vectors for targeted treatment

#128
20180161403
2018-06-14

ADENO-ASSOCIATED VIRUS FACTOR VIII VECTORS

#129
20180036431
2018-02-08

DELIVERY OF POLYNUCLEOTIDES USING RECOMBINANT AAV9

#130
20180036428
2018-02-08

Capsid modified rAAV vectors and methods of use

#131
20170369874
2017-12-28

RAAV-BASED COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTI-TRYPSIN DEFICIENCIES

#132
20170326256
2017-11-16

Recombinant promoters and vectors for protein expression in liver and use thereof

#133
20170304465
2017-10-26

Adeno-associated viral vectors for treating myocilin (MYOC) glaucoma

#134
20170266319
2017-09-21

METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH SPINAL CORD INJURY

#135
20170211094
2017-07-27

Recombinant adeno-associated vectors for targeted treatment

#136
20170211093
2017-07-27

Recombinant adeno-associated vectors for targeted treatment

#137
20170211092
2017-07-27

Recombinant adeno-associated vectors for targeted treatment

#138
20170159071
2017-06-08

RAAV-BASED COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTI-TRYPSIN DEFICIENCIES

#139
20170157213
2017-06-08

Efficient systemic treatment of dystrophic muscle pathologies

#140
20170130208
2017-05-11

Compositions and methods for purifying recombinant adeno-associated virus

#141
20170119829
2017-05-04

METHOD FOR INDUCING PRODUCTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR

#142
20170095538
2017-04-06

Adeno-associated virus factor VIII vectors

#143
20170073703
2017-03-16

Recombinant adeno-associated vectors for targeted treatment

#144
20170029849
2017-02-02

Recombinant virus products and methods for inhibition of expression of DUX4

#145
20160326524
2016-11-10

rAAV-based compositions and methods

#146
20160310618
2016-10-27

Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject

#147
20160228504
2016-08-11

S100 based treatment of cardiac power failure

#148
20160194374
2016-07-07

Recombinant AAV-crumbs homologue composition and methods for treating LCA-8 and progressive RP

#149
20160186211
2016-06-30

RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies

#150
20160186139
2016-06-30

Cell and gene based methods to improve cardiac function

#151
20160153005
2016-06-02

Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy

#152
20160153004
2016-06-02

DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETING AND MODELING DISEASES AND DISORDERS OF POST MITOTIC CELLS

#153
20160106865
2016-04-21

Capsid-modified rAAV vectors and methods of use

#154
20160082035
2016-03-24

Immunomodulating gene therapy

#155
20160076028
2016-03-17

Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs

#156
20160074532
2016-03-17

METHODS AND COMPOSITIONS FOR ATTENUATING GENE EDITING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES

#157
20160074531
2016-03-17

METHODS AND COMPOSITIONS FOR ATTENUATING GENE THERAPY ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES

#158
20160074372
2016-03-17

Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses

#159
20160068821
2016-03-10

Chimeric adeno-associated virus/ bocavirus parvovirus vector

#160
20160067228
2016-03-10

Methods and compositions for attenuating anti-viral transfer vector immune responses

#161
20160058890
2016-03-03

Selective gene therapy expression system

#162
20160038613
2016-02-11

Delivery of polynucleotides using recombinant AAV9

#163
20160032319
2016-02-04

Vectors comprising stuffer/filler polynucleotide sequences and methods of use

#164
20160024526
2016-01-28

METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE

#165
20160015288
2016-01-21

REAGENTS AND METHODS FOR MODULATING CONE PHOTORECEPTOR ACTIVITY

#166
20150376649
2015-12-31

Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same

#167
20150343038
2015-12-03

METHOD AND COMPOSITION FOR TREATING SPASTICITY

#168
20150322410
2015-11-12

HYPOXIA REGULATED CONDITIONALLY SILENCED AAV EXPRESSING ANGIOGENIC INDUCERS

#169
20150313969
2015-11-05

Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy due to Friedreich ataxia

#170
20150252358
2015-09-10

CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)

#171
20150132262
2015-05-14

Mutant adeno-associated virus virions and methods of use thereof

#172
20140377224
2014-12-25

Method of treating or retarding the development of blindness

#173
20140056854
2014-02-27

Viral vectors with modified transduction profiles and methods of making and using the same

#174
20130288976
2013-10-31

Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL

#175
20130225666
2013-08-29

Delivery of MECP2 polynucleotide using recombinant AAV9

#176
20130131152
2013-05-23

FROG/TOAD conditionally silenced vectors for hypoxia gene therapy

#177
20120225930
2012-09-06

METHOD OF TREATING OR RETARDING THE DEVELOPMENT OF BLINDNESS

#178
20120213736
2012-08-23

Parvovirus methods and compositions for killing neoplastic cells

#179
20120172419
2012-07-05

REAGENTS AND METHODS FOR MODULATING CONE PHOTORECEPTOR ACTIVITY

#180
20120156170
2012-06-21

DRUG COMPOSITION FOR ANGIOGENESIS THERAPY

#181
20110070220
2011-03-24

Immunomodulating gene therapy

#182
20110065779
2011-03-17

AAV VECTOR COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF IMMUNOGLOBULINS USING THE SAME

#183
20110034540
2011-02-10

CYP46A1 gene for the treatment of alzheimer's disease

#184
20110022131
2011-01-27

Method for Restoring an Ejaculatory Failure

#185
20100272688
2010-10-28

Method of treating or retarding the development of blindness

#186
20100104561
2010-04-29

Tyrosine-modified recombinant rAAV vector compositions and methods for use

#187
20090202490
2009-08-13

Mutant adeno-associated virus virions and methods of use thereof

#188
20090117081
2009-05-07

Parvovirus methods and compositions for killing neoplastic cells

#189
20090074723
2009-03-19

Method of Treating or Retarding the Development of Blindness

#190
20080131403
2008-06-05

Recombinant adeno-associated virus expressing human antisense gene CyP2J2 and its preparation methods

#191
20070077228
2007-04-05

Method of treating or retarding the development of blindness

#192
20060034805
2006-02-16

AAV vector compositions and methods for enhanced expression of immunoglobulins using the same

#193
20060002894
2006-01-05

Method for introducing a biological molecule using a viral envelope and heparin and system therefore